CGON (CG Oncology) EBITDA Margin %: -6,052.45% (As of Mar. 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $71.96
! 6 Warning Signs
View Full Analysis

What is CG Oncology EBITDA Margin %?

CG Oncology CGON -1.22% 12 EBITDA Margin % is -6,052.45% as of Mar. 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, CG Oncology ranks worse than 89.51% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. CG Oncology's EBITDA for the three months ended in Mar. 2026 was $-65.55 Mil. CG Oncology's Revenue for the three months ended in Mar. 2026 was $1.08 Mil. Therefore, CG Oncology's EBITDA margin for the quarter that ended in Mar. 2026 was -6,052.45%.

CG Oncology  (NAS:CGON) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

CG Oncology EBITDA Margin % Related Terms

CG Oncology EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for CG Oncology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology EBITDA Margin % Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
-119.50 -18,445.55 -27,172.55 -10,064.44 -4,686.36

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81,115.38 0.00 -3,044.00 -2,060.77 -6,052.45

CGON vs CRSP, XENE, TGTX: EBITDA Margin % Comparison

For the Biotechnology subindustry, CG Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where CG Oncology's EBITDA Margin % falls into.


CGON
12GF Score
CG Oncology Inc CGON
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

CG Oncology's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-189.329/4.04
=-4,686.36 %

CG Oncology's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-65.548/1.083
=-6,052.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -6,052.45% mean?
CG Oncology (CGON) has a EBITDA Margin % of -6,052.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CG Oncology and its competitors. According to the industry distribution chart, CG Oncology ranks #845 out of 944 companies in the Biotechnology industry, placing it in the top 89.5%.
Is CG Oncology's EBITDA Margin % too high?
CG Oncology's current EBITDA Margin % is -6,052.45%. Based on the distribution chart, CG Oncology ranks #845 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's EBITDA Margin % compare to CRSP and XENE?
According to the Biotechnology industry distribution chart, CG Oncology ranks #845 out of 944 companies for EBITDA Margin %. This places CG Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CG Oncology and its competitors. CG Oncology's current EBITDA Margin % is -6,052.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current EBITDA Margin % of -6,052.45%. The current EBITDA Margin % is -6,052.45%. CG Oncology's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CG Oncology (CGON), the current EBITDA Margin % is -6,052.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.96
Price